MyFinsight
Home
Blog
About
Borrowings under
short-term debt and notes ...
$1,068K
(178.85%↑ Y/Y)
Net restricted cash
and cash...
$1,046K
(-56.87%↓ Y/Y)
Canceled cashflow
$22K
Net change in
restricted cash and cash...
-$2,094K
(-30014.29%↓ Y/Y)
Canceled cashflow
$1,046K
Change in fair value of
financial instruments
-$5,745K
(-523.99%↓ Y/Y)
Loss on debt
extinguishment
-$2,192K
Accrued compensation
$682K
(378.37%↑ Y/Y)
Noncash interest
expense
$626K
(-46.27%↓ Y/Y)
Accrued expenses and
other liabilities
$600K
(16.73%↑ Y/Y)
Inventory write-down for
excess & obsolescence
$118K
(-33.71%↓ Y/Y)
Prepaid and other assets
-$83K
(-7.79%↓ Y/Y)
Loss on contingent
liability
$61K
(144.00%↑ Y/Y)
Noncash right-of-use
asset amortization
$32K
(-47.54%↓ Y/Y)
Accounts payable
$29K
(104.09%↑ Y/Y)
Amortization of intangible
asset
$14K
(-95.76%↓ Y/Y)
Depreciation
$4K
(-60.00%↓ Y/Y)
Payments under
short-term debt and notes ...
$22K
(-94.26%↓ Y/Y)
Net restricted cash
and cash...
-$3,140K
(-33.11%↓ Y/Y)
Canceled cashflow
$10,186K
Net loss
-$11,036K
(-1232.85%↓ Y/Y)
Trade accounts
receivable
$1,937K
(139.55%↑ Y/Y)
Inventories
$265K
(-47.73%↓ Y/Y)
Contingent liabilities
-$56K
(86.82%↑ Y/Y)
Operating lease
liabilities
-$32K
(48.39%↑ Y/Y)
Back
Back
Cash Flow
Evofem Biosciences, Inc. (EVFM)
Evofem Biosciences, Inc. (EVFM)
source: myfinsight.com